2 parties interested at 20.7 and 20.8c PPS. These are low ball offers to fully acquire the technology.
the parties have both priced in risk of execution getting the covid test to commercialisation. They see huge upside in this technology.
Just because a takeover bid gets knocked back doesn’t mean we won’t find commercial terms with these organisations moving forward.
pfizer and Resapp have been jointly developing a covid test for the past months. There’s obvious signs this technology is working and close to commercialisation or Pfizer would just start their own journey without us.
Still voting No as I believe we will have partners lining up now that Pfizer has validated the technology on a global scale by the takeover bid.
As management have said the test is only likely to take another $1M to refine with additional clinical studies already underway.
RAP Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
